Shrutidevi Agrawal
Overview
Explore the profile of Shrutidevi Agrawal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashokraj Y, Agrawal S, Panchagnula R
Indian J Pharm Sci
. 2010 Apr;
70(1):1-4.
PMID: 20390072
For centuries tuberculosis remained as a complex socioeconomic problem impeding human development. Directly observed treatment short-course and fixed dose combinations were implemented in tuberculosis therapy for maximum success of treatment....
2.
Mullangi R, Agrawal S, Srinivas N
Biomed Chromatogr
. 2008 Sep;
23(1):3-25.
PMID: 18816455
The use of saliva for measuring xenobiotic concentrations has been practiced for a number of years. While the use of saliva has been generally reserved for the analysis of diagnostic...
3.
Agrawal S, Panchagnula R
Biopharm Drug Dispos
. 2005 Aug;
26(8):321-34.
PMID: 16059874
Rifampicin is one of the oldest and most effective chemotherapeutic agents available for the treatment of tuberculosis but exhibits variable bioavailability from separate and fixed dose combination formulations, which has...
4.
Varma M, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, et al.
Curr Drug Metab
. 2004 Nov;
5(5):375-88.
PMID: 15544432
The tenets of biopharmaceutics, solubility and permeability, are of pivotal importance in new drug discovery and lead optimization due to the dependence of drug absorption and pharmacokinetics on these two...
5.
Agrawal S, Panchagnula R
Int J Pharm
. 2004 Nov;
287(1-2):97-112.
PMID: 15541917
The present investigation was aimed at developing a dissolution methodology to predict in vivo performance of rifampicin containing fixed dose combination (FDC) products. Six FDC formulations were used in this...
6.
Agrawal S, Singh I, Kaur K, Bhade S, Kaul C, Panchagnula R
Pharmacol Res
. 2004 Jul;
50(3):317-27.
PMID: 15225676
Rifampicin shows variable bioavailability from solid oral dosage forms and the reasons for this variable absorption reported in literature varies from extrinsic formulations factors to intrinsic variability in rifampicin absorption....
7.
Agrawal S, Ashokraj Y, Bharatam P, Pillai O, Panchagnula R
Eur J Pharm Sci
. 2004 May;
22(2-3):127-44.
PMID: 15158898
Polymorphism of rifampicin has been postulated to be responsible for its variable bioavailability from solid oral dosage forms. In this regard, it was believed that form II is the preferred...
8.
Panchagnula R, Agrawal S
Int J Pharm
. 2004 May;
271(1-2):1-4.
PMID: 15129967
Even today the treatment outcome of tuberculosis is questionable due to variable bioavailability of rifampicin, which was discovered four decades back. In this manuscript, results of bioequivalence trials reported are...
9.
Agrawal S, Singh I, Kaur K, Bhade S, Kaul C, Panchagnula R
Int J Pharm
. 2004 Apr;
276(1-2):41-9.
PMID: 15113612
Fixed dose combination (FDC) formulations became popular in the treatment of tuberculosis (TB) because of the better patient compliance, reduced risk of monotherapy and emergence of drug resistance in contrast...
10.
Panchagnula R, Sundaramurthy P, Pillai O, Agrawal S, Raj Y
J Pharm Sci
. 2004 Mar;
93(4):1019-29.
PMID: 14999737
The purpose of this study was to characterize mefenamic acid (MA) from commercial samples and samples crystallized from different solvents. Various techniques used for characterization included microscopy (hot stage microscopy,...